Eray Goekkurt

University Cancer Center Hamburg

3

h-index

4

Publications

4,954

Citations

Publications

3 shown

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong‐Mu Sun , Lin Shen , Manish A. Shah +22 more

Merck Sharp & Dohme.

2021 The Lancet 1394 citations

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara , Mustafa Özgüroğlu , Yung‐Jue Bang +97 more

2018 The Lancet 1262 citations

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Christian Caglevic , Luis J. Villanueva-Rivera , Eray Goekkurt +25 more

ClinicalTrials.gov Identifier: NCT02494583.

2020 JAMA Oncology 1036 citations

Frequent Co-Authors

Kohei Shitara

National Cancer Center Hospital East

Mustafa Özgüroğlu

Florida Hospital Cancer Institute

Yung‐Jue Bang

Seoul National University

Maria Di Bartolomeo

Fondazione IRCCS Istituto Nazionale dei Tumori

Mario Mandalà

Ospedale Papa Giovanni XXIII

Min‐Hee Ryu

Asan Medical Center

Researcher Info

h-index: 3
Publications: 4
Citations: 4,954
Institution: University Cancer Center Hamburg

External Links

Google Scholar

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.